A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 in Combination With Semaglutide

NCT06972992 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and side effects of the drug ASC47 when taken together with semaglutide in adults managing their weight long-term.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 28 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2025-04 · est. completion 2025-09

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT06972992 ↗

Description as written by the study sponsor.

This will be a phase I, randomized, double-blind, placebo-controlled. This study will be conducted in three periods: the screening period, the treatment period, and the follow-up period.

Treatments tested

ASC47 +Semaglutide Drug

ASC47 single subcutaneous injection + Semaglutide QW for 4 weeks
Placebo+Semaglutide Drug

Placebo single subcutaneous injection + Semaglutide QW for 4 weeks

Main thing measured	Adverse events
Sponsor	Ascletis Pharma (China) Co., Limited
Conditions studied	Chronic Weight Management
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06972992 ↗